[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340053-105":59,"doc-detail-340053-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antitumor-activities-of-anticd44-monoclonal-antibodies-in-mouse-xenograft-models-of-esophageal-cancer","Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer","","CD44 is a type I transmembrane glycoprotein linked to poor prognosis in many solid tumors, where it regulates cell adhesion, survival, proliferation, and stemness, making it a therapeutic target. Anti‑CD44 monoclonal antibodies have been developed for antibody‑drug conjugates and CAR‑T strategies. This study generated mouse IgG2a versions of anti‑pan‑CD44 mAbs (5‑mG2a and C44Mab‑46‑mG2a) and evaluated their antitumor effects against CD44‑positive cells in vitro and in mouse models. Both mAbs bound CD44s‑overexpressed CHO‑K1 (CHO/CD44s) and KYSE770 by flow cytometry, activated effector cells, and showed complement‑dependent cytotoxicity. In xenografts, 5‑mG2a and C44Mab‑46‑mG2a significantly suppressed tumor development versus control IgG2a, supporting their promise as therapeutic regimens.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antitumor-activities-of-anticd44-monoclonal-antibodies-in-mouse-xenograft-models-of-esophageal-cancer/340053/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antitumor-activities-of-anticd44-monoclonal-antibodies-in-mouse-xenograft-models-of-esophageal-cancer/340053.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the role of CD44 in solid tumors and why is it considered a target?","Question",{"text":112,"@type":113},"CD44 is associated with poor prognosis and contributes to malignant progression by regulating cell adhesion, survival, proliferation, and stemness. Its functional importance and signaling involvement make it a target for tumor therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What antibodies were generated and how were they evaluated in this study?",{"text":117,"@type":113},"The study generated mouse IgG2a versions of anti‑pan‑CD44 mAbs, including 5‑mG2a and C44Mab‑46‑mG2a. They were assessed for binding to CD44s‑overexpressed cells and esophageal tumor cells by flow cytometry, for effector activation, and for complement‑dependent cytotoxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the in vivo findings in mouse xenograft models?",{"text":121,"@type":113},"Administration of 5‑mG2a and C44Mab‑46‑mG2a significantly suppressed CHO/CD44s and KYSE770 xenograft tumor development compared with control mouse IgG2a, indicating antitumor activity against CD44‑positive cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340053,1790198636,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ONCOLOGY REPORTS 52: 147, 2024  \nAntitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer  \nKENICHIRO ISHIKAWA 1,2 , HIROYUKI SUZUKI 1 , TOMOKAZU OHISHI3,4 , TAKURO NAKAMURA 1 , MIYUKI YANAKA 1 , GUANJIE LI 1 , TOMOHIRO TANAKA 1 , AKIRA OHKOSHI2 , MANABU KAWADA4 , MIKA K. KANEKO 1 , YUKIO KATORI2 and YUKINARI KATO 1  \n1  \nDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan; Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai,  \n2  \n3  \nMiyagi 980‑8575, Japan; Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu, Shizuoka 410‑0301, Japan; 4Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, Shinagawa‑ku, Tokyo 141‑0021, Japan  \nReceived April 18, 2024; Accepted July 23, 2024  \nDOI: 10. 3892/or.2024.8806  \nAbstract. CD44 is a type I transmembrane glycoprotein associated with poor prognosis in various solid tumors. Since CD44 plays a critical role in tumor development by regulating cell adhesion, survival, proliferation and stemness, it has been considered a target for tumor therapy. Anti‑CD44 mono‑ clonal antibodies (mAbs) have been developed and applied to antibody‑drug conjugates and chimeric antigen receptor‑T cell therapy. Anti‑pan‑CD44 mAbs, C44Mab‑5 and C44Mab‑46, which recognize both CD44 standard (CD44s) and variant isoforms were previously developed. The present study gener‑ ated a mouse IgG2a version of the anti‑pan‑CD44 mAbs (5‑mG2a and C44Mab‑46‑mG2a) to evaluate the antitumor activities against CD44‑positive cells. Both 5‑mG2a andC44Mab‑46‑mG2a recognized CD44s‑overexpressed CHO‑K1 (CHO/CD44s) cells and esophageal tumor cell line (KYSE770) in flow cytometry. Furthermore, both 5‑mG2a and C44Mab‑46‑mG2a could activate effector cells in the presence of CHO/CD44s cells and exhibited complement‑dependent cytotoxicity  \nCorrespondence to: Dr Yukinari Kato, Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2‑1, Seiryo‑machi, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan  \nE‑mail: [yukinari.kato.e6@tohoku.ac.jp](yukinari.kato.e6@tohoku.ac.jp)  \nAbbreviations: CD44s, CD44 standard; CD44v, CD44 variant; HA, hyaluronic acid; mAb, monoclonal antibody; ADCC, antibody‑ dependent cellular cytotoxicity; CDC, complement‑dependent cytotoxicity; FcγR, Fcγ receptor; CAR, chimeric antigen receptor; FUT8, fucosyl‑transferase 8; CHO, Chinese hamster ovary; CBIS, Cell‑Based Immunization and Screening; ESCC, esophageal squamous cell carcinoma; PBS, phosphate‑buffered saline  \nKey words: CD44, mAb, ADCC, CDC, esophageal tumor, antitumor activity  \nagainst both CHO/CD44s and KYSE770 cells. Furthermore, the administration of 5‑mG2a and C44Mab‑46‑mG2a signifi‑ cantly suppressed CHO/CD44s and KYSE770 xenograft tumor development compared with the control mouse IgG2a . These results indicate that 5‑mG2a and C44Mab‑46‑mG2a could exert antitumor activities against CD44‑positive cancers and be a promising therapeutic regimen for tumors.  \nIntroduction  \nOverexpression of CD44 is observed in various solid tumors, which are involved in the tumor malignant progression through the promotion of cellular proliferation, invasiveness and stem‑ ness via specific signaling pathways (1). The diversity of CD44 molecular function is mediated by the alternative splicing (2) . CD44 is encoded in 20 exons. The first five (1‑5) and the last five (16‑20) are constant exons that generate the shortest CD44 standard (CD44s) isoform . The exons 6‑15 are alternatively spliced and inserted into the CD44s as variant exons (3) . The CD44 splice variants with variant exons are designated CD44 variant (CD44v) isoforms. The inclusion of CD44v exons in various combinations is regulated by receptor tyrosine kinase signaling and splicing activators of pre‑mRNA (1) .","cbCaivFdIQywr47A","https://ap.wps.com/l/cbCaivFdIQywr47A","pdf",4184549,"English","# Abstract\n# Introduction\n## CD44 structure and isoforms\n## CD44 expression and prognosis\n## Anti‑CD44 monoclonal antibodies in research","[{\"question\":\"What is the role of CD44 in solid tumors and why is it considered a target?\",\"answer\":\"CD44 is associated with poor prognosis and contributes to malignant progression by regulating cell adhesion, survival, proliferation, and stemness. Its functional importance and signaling involvement make it a target for tumor therapy.\"},{\"question\":\"What antibodies were generated and how were they evaluated in this study?\",\"answer\":\"The study generated mouse IgG2a versions of anti‑pan‑CD44 mAbs, including 5‑mG2a and C44Mab‑46‑mG2a. They were assessed for binding to CD44s‑overexpressed cells and esophageal tumor cells by flow cytometry, for effector activation, and for complement‑dependent cytotoxicity.\"},{\"question\":\"What were the in vivo findings in mouse xenograft models?\",\"answer\":\"Administration of 5‑mG2a and C44Mab‑46‑mG2a significantly suppressed CHO/CD44s and KYSE770 xenograft tumor development compared with control mouse IgG2a, indicating antitumor activity against CD44‑positive cancers.\"}]","Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer | PDF",1790033938,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fce6f23678fff44c664d0fd83ae82b27.webp",983,1357,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7083816653caa737daf4259383d470d7.webp",982,1356,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1c3739a231981bca3290fbae8754d08.webp",981,1354,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fdede73cde7885303a77a23d925cb10.webp",980,1353]